Dave Adam continues to be a champion for Alzheimer’s disease research. Dave is a Wisconsin man who cycled across Canada last year to help raise funds for Alzheimer’s disease programs at UW–Madison. This year he’s going down under to Australia and plans to bike 2,500 miles to support the UW Initiative to End Alzheimer’s.
News
Announcing the IEA Innovation Fund
The UW Initiative to End Alzheimer’s (IEA) is pleased to announce the IEA Innovation Fund, providing project support for researchers from the Wisconsin Alzheimer’s Disease Research Center (ADRC) or Wisconsin Alzheimer’s Institute (WAI). The IEA Innovation Fund will help advance the University of Wisconsin–Madison’s Alzheimer’s disease researchers’ most promising ideas by providing an open door to funding opportunities that foster translational, innovative and inclusive advancements in Alzheimer’s disease research.
A closer look at lecanemab
In January, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway to treat Alzheimer’s disease. Nathaniel Chin, MD, recently interviewed Cynthia Carlsson, MD, MS, and Sterling Johnson, PhD, to inform people about the research behind the new Alzheimer’s treatment, the drug’s benefits and risks, and more.
UW study focuses on Alzheimer’s disease treatment and prevention in the Black community
Carey Gleason, PhD, MS, and her research team’s African Americans Fighting Alzheimer’s in Midlife (AA-FAIM) study is entering its second, five-year cycle and they are focused on making Alzheimer’s research more inclusive.
Dr. Maria Mora Pinzon appointed to assistant professor
Maria Mora Pinzon, MD, MS, FACPM, was recently appointed to assistant professor on the tenure track in the Division of Geriatrics and Gerontology at the University of Wisconsin School of Medicine and Public Health, where she will continue working with the Wisconsin Alzheimer’s Institute and expand her research program.
Introducing Lecanemab, the Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval
On the latest episode of the podcast, Dementia Matters, host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials.
Dr. Nathaniel Chin discusses the FDA approval of Leqembi on WPR
Nathaniel Chin, MD, joined host Rob Ferrett on the call-in program “Central Time” on The Ideas Network of Wisconsin Public Radio. Chin discussed the recent FDA approval of the drug Leqembi (lecanemab) to help with early Alzheimer’s and answered callers’ questions.
Dr. Cynthia Carlsson discusses the FDA approval of Leqembi
Cynthia Carlsson, MD, MS, was recently interviewed by CBS 58 News in Milwaukee about the U.S. Food and Drug Administration (FDA)
approval of Leqembi (lecanemab), which showed a reduction of clinical decline in a study of people with early Alzheimer’s disease.
FDA approves Alzheimer’s disease drug lecanemab
On January 6, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.
Dr. Sanjay Asthana appointed to serve on the National Advisory Council on Aging
Sanjay Asthana, MD, is the founding director of the Wisconsin Alzheimer’s Disease Research Center (ADRC) and an internationally renowned researcher and leader in the field of Alzheimer’s disease. The US Secretary of Health and Human …